VIVIMEDLAB2024-04-012024-06-30 VIVIMEDLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member VIVIMEDLAB2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532660 VIVIMEDLAB na Vivimed Labs Limited Equity 2024-04-01 2025-03-31 2025-01-10 2025-01-04 INR Millions First quarter 16:00:00 23:50:00 2025-01-10 2025-01-10 Not applicable Single segment Pharma Business 2024-04-01 2024-06-30 Unaudited Consolidated 293730000.00 600000.00 294330000.00 198170000.00 0.00 -24620000.00 60280000.00 2970000.00 40090000.00 99320000.00 376210000.00 -81880000.00 0.00 -81880000.00 0.00 0.00 0.00 0.00 -81880000.00 0.00 0.00 0.00 0.00 -81880000.00 0.00 -81880000.00 0.00 0.00 0.00 0.00 165830000.00 2 -0.99 -0.96 0.00 0.00 -0.99 -0.96 NOTES 1. The above standalone financial results of Vivimed Labs Limited ( the Company ) as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 10, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed an unmodified conclusion thereon. 2. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ('IND-AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ( SEBI ). 3. In line with provisions of IND-AS 108 Operating segments, the Company has primarily in Pharma Segment and accordingly the segemtn reporting is not applicable to the company. 4. The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs.3,746.46 million as on 30.06.2024 as per books of Account. All the loan accounts outstanding as on 30.06.2024 are classified as NPA by the banks. In view of ongoing negotiation with Lenders for One Time Settlement, interest for the perriod is not accounted. 5. The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and published year to date figures up to third quarter of the financial year ended March 31, 2024. 6. Corresponding numbers of previous period / year have been regrouped, wherever necessary. Other Expenses 99320000.00 0.00 0.00